STOCK TITAN

Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. disclosure: Wellington Management-related entities report beneficial ownership of 3,095,700 shares of Common Stock, representing 5.23% of the class as of 03/31/2026. The shares are held of record for clients of Wellington investment advisers and voting/dispositive power is shared across affiliated entities.

Positive

  • None.

Negative

  • None.

Insights

Wellington affiliates report a >5% passive stake in STOK.

Wellington Management Group LLP and affiliated holding entities disclose beneficial ownership of 3,095,700 shares, representing 5.23% as of 03/31/2026. The filing states the shares are owned of record by clients of Wellington investment advisers.

Shared voting and dispositive power is reported across multiple Wellington entities; the filing attributes record ownership to client accounts rather than to a single proprietary holder. Subsequent disclosures or amendments would show any change in percent or voting structure.

Disclosure clarifies control structure and indirect holdings.

The schedule lists several affiliated entities (Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP) and explains parent/subsidiary relationships and adviser roles. It also states that no client is known to hold >5% separately.

This is a passive ownership disclosure under Schedule 13G; the filing preserves the record that clients, via advisers, hold the economic interest and that voting/dispositive powers are shared among affiliates.

Shares beneficially owned 3,095,700 shares reported as beneficial ownership on cover pages
Percent of class 5.23% percent of common stock as stated in Item 4(b)
Record date 03/31/2026 date tied to the cover page reporting
Shared voting power 2,889,524 shares shared voting power reported on cover pages
Shared dispositive power 3,095,700 shares shared dispositive power reported on cover pages
beneficially owned regulatory
"Amount beneficially owned: See the responses to Item 9 on the attached cover pages."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive power regulatory
"Shared Dispositive Power 3,095,700.00"
Schedule 13G regulatory
"Item 1. (a) Name of issuer: Stoke Therapeutics, Inc."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
owned of record by clients financial
"The securities ... are owned of record by clients of the Wellington Investment Advisers."





86150R107

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026
Wellington Group Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026
Wellington Investment Advisors Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026
Wellington Management Company LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026

FAQ

What stake does Wellington report in STOK?

Wellington-related entities report beneficial ownership of 3,095,700 shares, representing 5.23% of Stoke Therapeutics' common stock as of 03/31/2026. The shares are owned of record by clients of Wellington investment advisers.

Which Wellington entities are named in the STOK filing?

The filing names Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP as reporting persons and affiliated advisers controlling the recorded client holdings.

Does any single Wellington client hold more than 5% of STOK?

The filing states no client is known to have the right to dividends or proceeds with respect to more than 5% of the class, and lists the aggregated client holdings as the record owner for the advisers.

What voting and dispositive powers are reported by Wellington?

The schedule reports shared voting power and shared dispositive power across the Wellington affiliates (e.g., 2,889,524 shared voting, 3,095,700 shared dispositive shown on cover pages). Sole voting/dispositive power is reported as 0.